MedImmune Inc, Connaught Laboratories Inc deal

The companies amended a 1992 agreement under which MEDI reacquired from the pharma company the rights to market CytoGam (cytomegalovirus immune globulin intravenous). The amendment includes an undisclosed reduction in the royalty rate paid by MEDI to Connaught on sales of CytoGam after Sept. 30, 1995, and an agreement under which Connaught will fill and package MEDI's immune globulin products through 1998.

MEDI will pay $2.7 million to Connaught upon completion of certain modifications of Connaught's filling and packaging facility. MEDI will expense the payment in the fourth quarter ended Dec. 31, 1995. ...